HIF-1α Stabilization for Hyperoxia-Induced Neonatal Lung Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Premature birth leads to chronic lung disease of prematurity (CLD), characterized by impaired lung development and function, with high oxygen supplementation being a major contributor, and current treatments are ineffective and costly, costing approximately 2.4 billion annually in the US.
Innovation Solution
The stabilization of Hypoxia-Inducible Factor 1-alpha (HIF-1α) through the use of HIF prolyl hydroxylase inhibitors like roxadustat and dimethyloxalylglycine (DMOG), which are administered intermittently to preterm neonates during oxygen supplementation to prevent or reduce the severity of CLD by normalizing alveolar development and lung function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high oxygen supplementation is administered to premature infants, then survival is improved, but lung development is impaired leading to chronic lung disease
Solution Approach 1:
The patent introduces HIF-1α as a molecular mediator that senses oxygen levels and triggers protective responses. By stabilizing HIF-1α during hyperoxia, the body activates protective pathways (angiogenesis, anti-inflammation) that mitigate oxygen toxicity while allowing necessary oxygen supplementation for survival
Solution Approach 2:
The patent changes the physiological parameter of HIF-1α stability under hyperoxia conditions. Normally HIF-1α is degraded in high oxygen, but the invention maintains its stability through PHD inhibition or genetic modification, thereby altering the cellular response to hyperoxia from damaging to protective
2Reliability
If mechanical ventilation and supplemental oxygen are used, then premature infants can survive, but alveolar development is arrested
Solution Approach 1:
The patent applies HIF-1α stabilization preemptively during the critical period of oxygen supplementation and mechanical ventilation. This preliminary protective action prevents alveolar developmental arrest before it occurs, rather than attempting to correct it after damage has been done
Solution Approach 2:
HIF-1α acts as an intermediary signaling molecule that coordinates between the mechanical ventilation environment and alveolar development processes. By maintaining HIF-1α stability, the patent enables communication that promotes continued alveolarization despite the stress of mechanical ventilation and supplemental oxygen
3Reliability
If HIF-1α is stabilized during hyperoxia, then lung development is protected, but current treatments are costly and ineffective
Solution Approach 1:
The patent employs small molecule PHD inhibitors that can be administered as intermittent courses rather than continuous expensive therapies. These relatively simple chemical compounds provide temporary HIF-1α stabilization during critical periods, offering a cost-effective alternative to prolonged intensive care
Solution Approach 2:
Instead of continuous expensive intervention, the patent applies HIF-1α stabilization periodically during specific critical windows (e.g., during oxygen supplementation phases). This intermittent approach reduces overall treatment cost while maintaining effectiveness during the most vulnerable periods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Interruption of HIF-1α breakdown in high oxygen conditions stabilizes lung development, reducing alveolar enlargement, mast cell infiltration, and improving lung compliance, thereby mitigating the long-term effects of hyperoxia-induced lung damage and potentially preventing asthma and COPD later in life.
Implementation Method 1
The stability of HIF-1α is regulated principally through hydroxylation of proline residues by prolyl hydroxylase domain-containing proteins (PHDs). In hyperoxia the HIF PHDs are activated causing the breakdown of HIF-1α.
Implementation Method 2
HIF-1α protein is highly regulated by oxygen and is rapidly degraded. The stabilization of Hypoxia-Inducible Factor 1-alpha (HIF-1α) through the use of HIF prolyl hydroxylase inhibitors like roxadustat and dimethyloxalylglycine (DMOG)
Data Source
AI summary
The disclosure provides a method comprising administering HIF stabilizing small molecule drugs to premature infants, whose survival is dependent upon mechanical ventilation and/or supplemental oxygen, to counteract the pathological effects of hyperoxia on lung development. Data in a mouse model of hyperoxia-induced neonatal lung disease supports a treatment with a HIF stabilizer during high oxygen exposure protects the lung. HIF stabilizers can be administered via various routes, including in an aerosolized state using a ventilator, intravenous, intraperitoneal or subcutaneous injection.